Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focusing on cancer therapies, has announced new employment inducement grants. The Compensation Committee of the company's Board of Directors has granted three new employees options to purchase 21,100 shares of common stock at an exercise price of $18.01 per share, which was the closing price on August 23, 2024. Additionally, restricted stock units to acquire 10,550 shares of common stock were granted. These equity awards were issued under the company's 2020 Inducement Plan, approved by the Board in January 2020 under the 'inducement exception' of NYSE Listed Company Manual Rule 303A.08.
Arcus Biosciences (NYSE:RCUS), una società biofarmaceutica in fase clinica focalizzata sulle terapie oncologiche, ha annunciato nuove concessioni di incentivazione all'impiego. Il Comitato di Compensazione del Consiglio di Amministrazione della società ha concesso opzioni per l'acquisto di 21.100 azioni ordinarie a $18,01 per azione, che era il prezzo di chiusura del 23 agosto 2024. Inoltre, sono state concesse unità azionarie vincolate per acquisire 10.550 azioni ordinarie. Questi premi azionari sono stati emessi nell'ambito del Piano di Incentivazione 2020, approvato dal Consiglio a gennaio 2020 ai sensi dell' 'eccezione di incentivo' della Regola 303A.08 del Manuale delle Società Quotabili NYSE.
Arcus Biosciences (NYSE:RCUS), una empresa biofarmacéutica en etapa clínica centrada en terapias contra el cáncer, ha anunciado nuevas concesiones de incentivos laborales. El Comité de Compensación de la Junta Directiva de la compañía ha otorgado opciones para comprar 21,100 acciones de acciones ordinarias a un precio de ejercicio de $18.01 por acción, que fue el precio de cierre del 23 de agosto de 2024. Además, se otorgaron unidades de acciones restringidas para adquirir 10,550 acciones ordinarias. Estos premios de capital se emitieron bajo el Plan de Incentivos 2020, aprobado por la Junta en enero de 2020 bajo la 'excepción de incentivo' de la Regla 303A.08 del Manual de Empresas Cotizadas de NYSE.
Arcus Biosciences (NYSE:RCUS)는 암 치료에 중점을 둔 임상 단계의 생명공학 회사로, 새로운 고용 유인 보상을 발표했습니다. 회사 이사회의 보상위원회는 3명의 새로운 직원에게 21,100주의 일반주식 매입 옵션을 주당 $18.01의 행사 가격으로 부여했습니다. 이는 2024년 8월 23일의 종가였습니다. 또한, 10,550주의 일반주식 취득을 위한 제한된 주식 유닛이 부여되었습니다. 이러한 자본 상여는 2020 유인 계획에 따라 이행되었으며, 이는 2020년 1월 이사회에 의해 승인된 NYSE 상장 기업 매뉴얼 규칙 303A.08의 '유인 예외'에 해당합니다.
Arcus Biosciences (NYSE:RCUS), une entreprise biopharmaceutique en phase clinique axée sur les thérapies contre le cancer, a annoncé de nouvelles attributions d'incitation à l'emploi. Le Comité de Rémunération du Conseil d'Administration de l'entreprise a accordé à trois nouveaux employés des options pour acheter 21 100 actions ordinaires à un prix d'exercice de 18,01 $ par action, qui était le prix de clôture du 23 août 2024. De plus, des unités d'actions restreintes pour acquérir 10 550 actions ordinaires ont été accordées. Ces attributions d'équité ont été émises dans le cadre du Plan d'Incitation 2020, approuvé par le Conseil en janvier 2020 selon l' 'exception d'incitation' de la Règle 303A.08 du Manuel des Sociétés Cotées de NYSE.
Arcus Biosciences (NYSE:RCUS), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Krebstherapien konzentriert, hat neue Beschäftigungsanreizvergaben bekannt gegeben. Der Vergütungsausschuss des Unternehmensvorstands hat drei neuen Mitarbeitern Optionen zum Kauf von 21.100 Aktien zum Ausübungspreis von 18,01 $ pro Aktie gewährt, was dem Schlusskurs vom 23. August 2024 entspricht. Darüber hinaus wurden eingeschränkte Aktieneinheiten zum Erwerb von 10.550 Aktien gewährt. Diese Eigenkapitalvergütungen wurden im Rahmen des 2020 Incentive Plans ausgegeben, der im Januar 2020 vom Vorstand genehmigt wurde, gemäß der 'Inzentivausnahme' der NYSE-Notierungsrichtlinie Regel 303A.08.
- Arcus Biosciences is attracting new talent with equity incentives
- The company is utilizing its 2020 Inducement Plan to offer competitive compensation packages
- None.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b receptor), HIF-2a, CD39, and AXL. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.
Inducement PR
Source: Arcus Biosciences
View source version on businesswire.com: https://www.businesswire.com/news/home/20240826881267/en/
Investor Inquiries:
Pia Eaves
VP of Investor Relations & Strategy
(617) 459-2006
peaves@arcusbio.com
Media Inquiries:
Holli Kolkey
VP of Corporate Communications
(650) 922-1269
hkolkey@arcusbio.com
Source: Arcus Biosciences
FAQ
What stock options did Arcus Biosciences (RCUS) grant to new employees?
How many restricted stock units did Arcus Biosciences (RCUS) grant in the recent announcement?
What was the exercise price for the stock options granted by Arcus Biosciences (RCUS) on August 23, 2024?
Under which plan were the equity awards granted by Arcus Biosciences (RCUS)?
